Search results for "Azole"

showing 10 items of 2392 documents

Nasal airway in cleft-palate patients: acoustic rhinometric data

1997

The objective of this study was to investigate an instrumental assessment technique for acquiring reproducible, metric data on the nasal airway in cleft-palate associated nasal dysplasia. A consecutive sample of 23 unilateral, 17 bilateral CLP patients and 15 controls with subjective normal nasal patency from a cleft-palate rehabilitation centre were studied. A series of transnasal acoustic measurements (pressure wave: 55 dB for 2 ms) of nasal volume were performed before and after topical decongestion with 2 x 0.3 mg of xylometazoline. A standardized regimen of acoustic parameters of the nasal valve and the adjacent segment of the nasal cavity were calculated. The cleft side yielded a sign…

AdultNasal cavitymedicine.medical_specialtyAdolescentCleft Lipmedicine.medical_treatmentNoseRhinoplastyXylometazolineAcoustic rhinometryotorhinolaryngologic diseasesmedicineHumansLongitudinal StudiesChildNosemedicine.diagnostic_testbusiness.industryImidazolesNose Deformities AcquiredReproducibility of ResultsAcousticsHypertrophyrespiratory systemRhinoplastySurgeryCleft PalatePosterior segment of eyeballNasal DecongestantsNasal MucosaSoundmedicine.anatomical_structureOtorhinolaryngologySurgeryNasal CavityNasal ObstructionOral SurgeryRhinomanometryAirwaybusinessFollow-Up Studiesmedicine.drugJournal of Cranio-Maxillofacial Surgery
researchProduct

Erratum: Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

2005

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors. Exposure to hormonal therapy does not hamper later response to chemotherapy. Patients with locally advanced or metastatic, hormonal receptor positive or unknown, breast cancer were treated with oral anastrozole, until disease progression, followed by oral exemestane until new evidence of disease progression. The primary end point of the study was clinical benefit, defined as the sum of complete responses (CR), partial responses (PR) and >…

AdultOncologyCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAntineoplastic Agents Hormonalmedicine.medical_treatmentAdministration OralPhases of clinical researchAnastrozoleBreast NeoplasmsAnastrozoleMetastasischemistry.chemical_compoundbreast cancerBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsNitrilesClinical StudiesHumansMedicineAgedGynecologybusiness.industrysequential hormonal therapyCancerMiddle AgedTriazolesmedicine.diseaseMetastatic breast cancerAndrostadienesOncologychemistryChemotherapy AdjuvantHormonal therapyFemaleHormone therapyCorrigendumbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Efficacy and safety of lomitapide in familial chylomicronaemia syndrome

2022

Familial chylomicronaemia syndrome (FCS) is a rare autosomal recessive disorder, resulting in elevated triglycerides (TGs), abdominal pain and pancreatitis. Treatment options are limited. Lomitapide, a microsomal triglyceride transfer protein inhibitor, is approved for the treatment of homozygous familial hypercholesterolaemia. Whether its therapeutic use may be extended to FCS remains unknown. The aim of this study was to evaluate the efficacy and safety of lomitapide in adult patients with FCS.The open-label, single-arm 'LOCHNES' study of lomitapide in FCS enrolled patients18 years with genetically confirmed FCS, elevated fasting TG ≥ 750 mg/dL and history of pancreatitis. Patients were a…

AdultPancreatitiSettore MED/09 - Medicina InternaTriglycerideBenzimidazoleLomitapideAbdominal PainPancreatitisHyperlipoproteinemia Type I.HumansBenzimidazolesHyperlipoproteinemia Type ICardiology and Cardiovascular MedicineTriglyceridesFamilial chylomicronaemia syndromeHuman
researchProduct

Human Bertiella studeri in Spain, Probably of African Origin

1997

A mature tapeworm and gravid proglottids of Bertiella studeri were reported from the stools of a 33-year-old pregnant Spanish woman. The patient had spent the six months preceding this discovery in Kenya. The evidence suggests a case of parasitism imported to Spain from the African continent. The patient presented no symptoms related to the parasite and the discovery in stools of a number of active, white structures led her to collect them. A morphologic and morphometric description of the material obtained is presented. Mebendazole failed to remove the parasite but niclosamide was effective.

AdultPathologymedicine.medical_specialtyMebendazoleParasitismZoologyAfrican originPregnancyVirologymedicineAnimalsHumansParasite hostingNiclosamideTravelbusiness.industryAnticestodal AgentsCestode InfectionsInfectious DiseasesSpainPregnancy Complications ParasiticAfricaBertiella studeriCestodaNiclosamideFemaleParasitologybusinessmedicine.drugThe American Journal of Tropical Medicine and Hygiene
researchProduct

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report

2019

Abstract Background Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. Case presentation A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. Conclusion As far …

AdultPediatricsmedicine.medical_specialtyTime FactorsBipolar disordermedicine.medical_treatmentvirusesAripiprazoleCase Report030226 pharmacology & pharmacyInjections IntramuscularAntipsychotic03 medical and health sciences0302 clinical medicineimmune system diseasesPregnancylcsh:RA1190-1270medicineHumansPharmacology (medical)Bipolar disorderAntipsychoticlcsh:Toxicology. PoisonsPharmacologyDosage FormsPregnancybusiness.industrylcsh:RM1-950Pregnancy Outcomevirus diseasesCongenital malformationsmedicine.diseasePregnancy ComplicationsLong actinglcsh:Therapeutics. PharmacologyTreatment interruptionLong-acting injectable aripiprazoleAripiprazoleFemaleClinical casebusinessmedicine.drugAntipsychotic AgentsFollow-Up StudiesBMC Pharmacology and Toxicology
researchProduct

Four-phase rhinomanometry: a multicentric retrospective analysis of 36,563 clinical measurements

2015

Rhinomanometry can still be considered as the standard technique for the objective assessment of the ven- tilatory function of the nose. Reliable technical requirements are given by fast digital sensors and modern information technology. However, the xyimaging of the pressure-flow relation typically shows loops as a sign of hysteresis, with the need for resolution of the breath in four phases. The three pillars of 4-phase rhinomanometry (4PR) are the replacement of estimations by measurements, the introduc- tion of parameters related to the subjective sensing of obstruction, and the graphical information regarding the disturbed function of the nasal valve. In a meta-analysis of 36,563 clini…

AdultPercentilemedicine.medical_specialtyVisual Analog ScaleEffective resistanceVisual analogue scaleParameterNoseLogarithmic transformationWhite PeopleXylometazoline03 medical and health sciences0302 clinical medicineStatisticsRetrospective analysismedicineHumans030223 otorhinolaryngologyNosePain MeasurementRetrospective Studiesmedicine.diagnostic_testbusiness.industryAirway ResistanceImidazolesClinical validationGeneral MedicineRhinologyStandard techniqueRhinomanometryNasal DecongestantsMeta-analysismedicine.anatomical_structureOtorhinolaryngologyOtorhinolaryngology030220 oncology & carcinogenesisFour-phase rhinomanometryRegression AnalysisRhinomanometryNasal Obstructionbusinessmedicine.drugEuropean Archives of Oto-Rhino-Laryngology
researchProduct

Impaired Cardiopulmonary Exercise Capacity in Patients With Hyperthyroidism

1996

Hyperthyroidism (H) has been implicated as a primary cause of decreased exercise tolerance. To our knowledge, analysis of respiratory gas exchange, an efficient noninvasive method in evaluating cardiopulmonary capacity, has not been performed in patients with H.Using cardiopulmonary exercise testing, 12 consecutive women with Graves' H were examined and controlled in euthyroidism (E). Eighteen women with E, in whom cardiac catheterization had ruled out heart disease, served as control subjects (C).The ventilatory anaerobic threshold was determined by means of the V-slope method. Ergometry was performed with patients in a semisupine position using a continuous ramp protocol of 20 W/min. Echo…

AdultPulmonary and Respiratory MedicineCardiac outputmedicine.medical_specialtySupine positionAnaerobic ThresholdHeart diseaseRestmedicine.medical_treatmentPhysical exerciseCritical Care and Intensive Care MedicineOxygen ConsumptionAntithyroid AgentsHeart RateInternal medicineHeart rateSupine PositionTidal VolumemedicineHumansProspective StudiesCardiac OutputLungAgedCardiac catheterizationExercise ToleranceMethimazolePulmonary Gas Exchangebusiness.industryHeartStroke VolumeStroke volumeMiddle Agedmedicine.diseaseGraves DiseaseSurgeryEchocardiographyExercise TestLinear ModelsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAnaerobic exerciseChest
researchProduct

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, …

2012

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were…

AdultTime FactorsOriginalMigraine DisordersPopulationAlmotriptanClinical NeurologyCarbazolesSubgroup analysisSeverity of Illness IndexAdult; Carbazoles; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Italy; Menstruation Disturbances; Middle Aged; Migraine Disorders; Proportional Hazards Models; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors; Treatment Outcome; TryptaminesDisability EvaluationDouble-Blind MethodAlmotriptanSeverity of illnessMedicineHumanseducationMigraine Menstrually related migraine Frovatriptan AlmotriptanMenstrually related migraineMenstruation DisturbancesMigraineMenstrually related migraineProportional Hazards Modelseducation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTryptaminesSerotonin Receptor Agonistsfrovatriptan; migraine; menstrually related migraine; almotriptanAnesthesiology and Pain MedicineTreatment OutcomeMigraineItalyAnesthesiaFemaleNeurology (clinical)businessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Papular pruritic eruption with human immunodeficiency virus infection.

1991

Adultbusiness.industryPruritusHuman immunodeficiency virus (HIV)DermatitisHIV InfectionsDermatologymedicine.disease_causeVirologyMetronidazolemedicineHumansFemalebusinessZidovudineInternational journal of dermatology
researchProduct

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers

1993

Leflunomide (HWA 486), an isoxazol derivative, has been shown to be very effective in combating autoimmune diseases and transplantation rejection in a great number of animal models. The main metabolite of leflunomide, A77 1726, is a potent antiproliferative compound. To further elucidate this effect, lymphocytes of healthy human donors were cultured for 24, 48 or 72 h in the presence of PHA or immobilized anti-CD3 antibody. A77 1726 was added at concentrations between 10 and 100 microM. Flow cytometric evaluation of early activation or proliferation markers (IL-2 and transferrin receptors, respectively) showed that their expression was inhibited in a dose-dependent manner by A77 1726. Toget…

Adultmedicine.medical_specialtyAllergyToluidinesMetaboliteImmunologyHydroxybutyratesTransferrin receptorBiologyPharmacologyLymphocyte ActivationToxicologychemistry.chemical_compoundImmune systemInternal medicineNitrilesReceptors TransferrinmedicineHumansPharmacology (medical)PhytohemagglutininsLeflunomidePharmacologyAniline CompoundsAnti-Inflammatory Agents Non-SteroidalReceptors Interleukin-2Isoxazolesmedicine.diseaseRheumatologyTransplantationchemistryCrotonatesImmunologybiology.proteinAntibodyBiomarkersLeflunomidemedicine.drugAgents and Actions
researchProduct